189 related articles for article (PubMed ID: 8263538)
1. Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra.
Aime S; Fasano M; Bergamasco B; Lopiano L; Valente G
J Neurochem; 1994 Jan; 62(1):369-71. PubMed ID: 8263538
[TBL] [Abstract][Full Text] [Related]
2. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
[TBL] [Abstract][Full Text] [Related]
3. Isolation and 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson's disease.
Aime S; Bergamasco B; Casu M; Digilio G; Fasano M; Giraudo S; Lopiano L
Mov Disord; 2000 Sep; 15(5):977-81. PubMed ID: 11009208
[TBL] [Abstract][Full Text] [Related]
4. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.
Zecca L; Tampellini D; Gerlach M; Riederer P; Fariello RG; Sulzer D
Mol Pathol; 2001 Dec; 54(6):414-8. PubMed ID: 11724917
[TBL] [Abstract][Full Text] [Related]
5. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study.
Shima T; Sarna T; Swartz HM; Stroppolo A; Gerbasi R; Zecca L
Free Radic Biol Med; 1997; 23(1):110-9. PubMed ID: 9165303
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation.
Korytowski W; Sarna T; Zar ba M
Arch Biochem Biophys; 1995 May; 319(1):142-8. PubMed ID: 7771778
[TBL] [Abstract][Full Text] [Related]
8. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
9. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
Knörle R
Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
[TBL] [Abstract][Full Text] [Related]
10. Modifications of the iron-neuromelanin system in Parkinson's disease.
Fasano M; Bergamasco B; Lopiano L
J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
[TBL] [Abstract][Full Text] [Related]
11. Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra.
Gerlach M; Trautwein AX; Zecca L; Youdim MB; Riederer P
J Neurochem; 1995 Aug; 65(2):923-6. PubMed ID: 7616255
[TBL] [Abstract][Full Text] [Related]
12. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies.
Fasano M; Bergamasco B; Lopiano L
J Neural Transm (Vienna); 2006 Jun; 113(6):769-74. PubMed ID: 16755381
[TBL] [Abstract][Full Text] [Related]
13. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.
Ben-Shachar D; Youdim MB
J Neural Transm Suppl; 1990; 29():251-8. PubMed ID: 2193109
[TBL] [Abstract][Full Text] [Related]
14. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
[TBL] [Abstract][Full Text] [Related]
15. Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano-secondary ion mass spectrometry.
Biesemeier A; Eibl O; Eswara S; Audinot JN; Wirtz T; Pezzoli G; Zucca FA; Zecca L; Schraermeyer U
J Neurochem; 2016 Jul; 138(2):339-53. PubMed ID: 27121280
[TBL] [Abstract][Full Text] [Related]
16. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain.
Zecca L; Shima T; Stroppolo A; Goj C; Battiston GA; Gerbasi R; Sarna T; Swartz HM
Neuroscience; 1996 Jul; 73(2):407-15. PubMed ID: 8783258
[TBL] [Abstract][Full Text] [Related]
17. Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein.
Fasano M; Giraudo S; Coha S; Bergamasco B; Lopiano L
Neurochem Int; 2003 Jun; 42(7):603-6. PubMed ID: 12590943
[TBL] [Abstract][Full Text] [Related]
18. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients.
Lopiano L; Chiesa M; Digilio G; Giraudo S; Bergamasco B; Torre E; Fasano M
Biochim Biophys Acta; 2000 Mar; 1500(3):306-12. PubMed ID: 10699372
[TBL] [Abstract][Full Text] [Related]
19. Iron-binding characteristics of neuromelanin of the human substantia nigra.
Double KL; Gerlach M; Schünemann V; Trautwein AX; Zecca L; Gallorini M; Youdim MB; Riederer P; Ben-Shachar D
Biochem Pharmacol; 2003 Aug; 66(3):489-94. PubMed ID: 12907248
[TBL] [Abstract][Full Text] [Related]
20. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
